Abraxane 100 MG Injection
- RxCUI
- 583218
- RxNorm name
- Abraxane 100 MG Injection
- Display name
- Abraxane 100 MG Injection
- Full name
- Abraxane 100 MG Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:50
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ABRAXANE | PACLITAXEL | Abraxis BioScience, LLC | 24d10449-2936-4cd3-b7db-a7683db721e4 | 2022-10-31 | Boxed warning, Warnings, Adverse reactions | 583218 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 24d10449-2936-4cd3-b7db-a7683db721e4 | Abraxane 100 MG Injection | SY | 37 | These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing information for ABRAXANE. ABRAXANE ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), for intravenous use Initial U.S. Approval: 2005 | 20221031 |
| 24d10449-2936-4cd3-b7db-a7683db721e4 | Abraxane 100 MG Injection | PSN | 37 | These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing information for ABRAXANE. ABRAXANE ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), for intravenous use Initial U.S. Approval: 2005 | 20221031 |
| 24d10449-2936-4cd3-b7db-a7683db721e4 | paclitaxel 100 MG Injection [Abraxane] | SBD | 37 | These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing information for ABRAXANE. ABRAXANE ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), for intravenous use Initial U.S. Approval: 2005 | 20221031 |